Skip to main content
Erschienen in: Tumor Biology 7/2014

01.07.2014 | Research Article

Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity

verfasst von: Fengqing Hu, Zhen Tao, Zhenya Shen, Xiaolin Wang, Fei Hua

Erschienen in: Tumor Biology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Eph/ephrin signaling system plays a very important role in the tumorigenesis and the formation of blood vessel. However, the function of EphB4 and its ligand ephrin B2 in the carcinogenesis of esophageal squamous cell carcinoma (ESCC) is not fully understood. Here, it was found that the expression of EphB4 was up-regulated in ESCC tissues compared with the paired normal tissues, while ephrin B2 was down-regulated in ESCC samples. Phosphorylation of EphB4 induced by its ligand ephrin B2-Fc inhibited the growth, migration and colony formation of ESCC cells. Moreover, over-expression of EphB4 or EphB4 kinase dead mutant (EphB4 KD) in ESCC cells promoted cell growth and migration, suggesting EphB4 promoted cell growth and migration independent of its kinase activity. Furthermore, we found that EphB4 interacted with the adaptor protein RACK1 and RACK1 decreased the phosphorylation level of EphB4. Taken together, our study revealed the important function and regulation of EphB4 in the progression of ESCC and suggested EphB4 as a novel target for the treatment of ESCC.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2012;60:277–300.CrossRef Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2012;60:277–300.CrossRef
3.
Zurück zum Zitat Tachibana M, Kinugasa S, Yoshimura, et al. Extended esophagectomy with 3-field lymph node dissection for esophageal cancer. Arch Surg. 2003;138:1383–9.CrossRefPubMed Tachibana M, Kinugasa S, Yoshimura, et al. Extended esophagectomy with 3-field lymph node dissection for esophageal cancer. Arch Surg. 2003;138:1383–9.CrossRefPubMed
4.
Zurück zum Zitat Kopreski MS, Witters L, Brennan WAJ, et al. Protein tyrosine kinase activity in breast cancer and its relation to prognostic indicators. Anticancer Res. 1996;16:3037–41.PubMed Kopreski MS, Witters L, Brennan WAJ, et al. Protein tyrosine kinase activity in breast cancer and its relation to prognostic indicators. Anticancer Res. 1996;16:3037–41.PubMed
5.
Zurück zum Zitat Lindberg RA, Hunter T. cDNA cloning and characterization of eck, an epithelial cell receptor protein tyrosine kinase in the eph/elk family of protein kinase. Mol Cell Biol. 1990;10:6316–24.PubMedCentralPubMed Lindberg RA, Hunter T. cDNA cloning and characterization of eck, an epithelial cell receptor protein tyrosine kinase in the eph/elk family of protein kinase. Mol Cell Biol. 1990;10:6316–24.PubMedCentralPubMed
6.
Zurück zum Zitat Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004;15:419–33.CrossRefPubMed Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004;15:419–33.CrossRefPubMed
7.
Zurück zum Zitat Kim YH, Hu H, Guevara GS, et al. Artery and vein size is balanced by Notch and ephrin B2/B4 during angiogenesis. Development. 2008;135:3755–64.PubMedCentralCrossRefPubMed Kim YH, Hu H, Guevara GS, et al. Artery and vein size is balanced by Notch and ephrin B2/B4 during angiogenesis. Development. 2008;135:3755–64.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Bruhl T, Urbich C, Aicher D, et al. Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ Res. 2004;94:743–51.CrossRefPubMed Bruhl T, Urbich C, Aicher D, et al. Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ Res. 2004;94:743–51.CrossRefPubMed
9.
Zurück zum Zitat Steinle JJ, Meininger CJ, Forough R, et al. EphB4 receptor signaling mediates endothelial cell migration and proliferation via PI3K pathway. J Biol Chem. 2002;277:43830–5.CrossRefPubMed Steinle JJ, Meininger CJ, Forough R, et al. EphB4 receptor signaling mediates endothelial cell migration and proliferation via PI3K pathway. J Biol Chem. 2002;277:43830–5.CrossRefPubMed
10.
Zurück zum Zitat Hasina R, Mollberg N, Kawada I. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013;73:184–94.CrossRefPubMed Hasina R, Mollberg N, Kawada I. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013;73:184–94.CrossRefPubMed
11.
Zurück zum Zitat Hu HQ, Tao Z, Wang MS, et al. RACK1 promoted the growth and migration of the cancer cells in the progression of esophageal squamous cell carcinoma. Tumor Biol. 2013;34:3893–9.CrossRef Hu HQ, Tao Z, Wang MS, et al. RACK1 promoted the growth and migration of the cancer cells in the progression of esophageal squamous cell carcinoma. Tumor Biol. 2013;34:3893–9.CrossRef
12.
Zurück zum Zitat Xia G, Kumar SR, Masood R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623–32.CrossRefPubMed Xia G, Kumar SR, Masood R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623–32.CrossRefPubMed
13.
Zurück zum Zitat Xia G, Kumar SR, Stein JP, et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006;25:769–80.CrossRefPubMed Xia G, Kumar SR, Stein JP, et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006;25:769–80.CrossRefPubMed
14.
Zurück zum Zitat Kumar SR, Masood R, Spannuth WA, et al. The receptor tyrosine kinase Ephb4 is overexpressed in ovarian cancer, provides signals and predicts poor outcome. Br J Cancer. 2007;96:1083–91.PubMedCentralCrossRefPubMed Kumar SR, Masood R, Spannuth WA, et al. The receptor tyrosine kinase Ephb4 is overexpressed in ovarian cancer, provides signals and predicts poor outcome. Br J Cancer. 2007;96:1083–91.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Noren NK, Foos G, Hauser CA, et al. The EphB4 receptor suppresses breast cancer cell tumorigenecity through an Abl–Crk pathway. Nat Cell Biol. 2006;8:815–25.CrossRefPubMed Noren NK, Foos G, Hauser CA, et al. The EphB4 receptor suppresses breast cancer cell tumorigenecity through an Abl–Crk pathway. Nat Cell Biol. 2006;8:815–25.CrossRefPubMed
16.
Zurück zum Zitat Deng YZ, Yao F, Li JJ, et al. RACK1 Suppresses gastric tumorigenesis by stabilizing beta-catenin destruction complex. Gastroenterology. 2012;142:812–23.CrossRefPubMed Deng YZ, Yao F, Li JJ, et al. RACK1 Suppresses gastric tumorigenesis by stabilizing beta-catenin destruction complex. Gastroenterology. 2012;142:812–23.CrossRefPubMed
17.
Zurück zum Zitat Li G, Ji XD, Gao H, et al. EphB3 mediates kinase-dependent suppression of non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signaling complex. Nat Commun. 2012;3:667. doi:10.1038/ncomms1675.CrossRefPubMed Li G, Ji XD, Gao H, et al. EphB3 mediates kinase-dependent suppression of non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signaling complex. Nat Commun. 2012;3:667. doi:10.​1038/​ncomms1675.CrossRefPubMed
Metadaten
Titel
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity
verfasst von
Fengqing Hu
Zhen Tao
Zhenya Shen
Xiaolin Wang
Fei Hua
Publikationsdatum
01.07.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1955-4

Weitere Artikel der Ausgabe 7/2014

Tumor Biology 7/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.